Verve Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Verve Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||
| current assets: | ||||||||||||||||
| cash and cash equivalents | 96,554,000 | 172,560,000 | 158,709,000 | 141,490,000 | 144,200,000 | 206,180,000 | 78,370,000 | 70,042,000 | 83,746,000 | 115,412,000 | 277,019,000 | 72,889,000 | 91,420,000 | 64,330,000 | 148,134,000 | 387,446,000 |
| marketable securities | 400,523,000 | 351,721,000 | 381,211,000 | 434,458,000 | 462,167,000 | 417,770,000 | 406,856,000 | 392,434,000 | 424,941,000 | 439,396,000 | 273,691,000 | 220,672,000 | 231,879,000 | 296,112,000 | 241,076,000 | 30,178,000 |
| collaboration receivable | 1,399,000 | 3,255,000 | 2,628,000 | 3,040,000 | 5,767,000 | 5,897,000 | 3,145,000 | 2,093,000 | 1,404,000 | 1,012,000 | 929,000 | |||||
| prepaid expenses and other current assets | 13,174,000 | 15,215,000 | 13,911,000 | 11,899,000 | 8,192,000 | 8,102,000 | 9,890,000 | 8,497,000 | 7,696,000 | 7,339,000 | 9,991,000 | 5,083,000 | 5,531,000 | 6,686,000 | 5,227,000 | 1,940,000 |
| total current assets | 511,650,000 | 542,751,000 | 556,459,000 | 590,887,000 | 620,326,000 | 637,949,000 | 498,261,000 | 473,066,000 | 517,787,000 | 563,159,000 | 561,630,000 | 298,644,000 | 328,830,000 | 367,128,000 | 394,437,000 | 419,564,000 |
| property and equipment | 18,457,000 | 18,644,000 | 19,625,000 | 20,195,000 | 21,024,000 | 22,505,000 | 20,803,000 | 21,252,000 | 21,053,000 | 18,778,000 | 15,159,000 | 12,354,000 | 11,132,000 | 7,224,000 | 6,574,000 | 6,417,000 |
| restricted cash | 4,774,000 | 4,774,000 | 4,774,000 | 4,774,000 | 4,774,000 | 4,774,000 | 4,774,000 | 4,824,000 | 4,824,000 | 4,824,000 | 4,824,000 | 5,237,000 | 5,237,000 | 5,237,000 | 5,237,000 | 463,000 |
| operating lease right-of-use assets | 76,217,000 | 78,082,000 | 79,921,000 | 81,736,000 | 83,527,000 | 85,295,000 | 87,041,000 | 88,766,000 | 90,003,000 | 91,877,000 | 91,332,000 | 839,000 | 1,340,000 | 1,839,000 | 2,335,000 | |
| other long term assets | 3,065,000 | 3,141,000 | 3,127,000 | 3,318,000 | 2,706,000 | 2,165,000 | 1,528,000 | 1,223,000 | 585,000 | 7,193,000 | 2,702,000 | 2,696,000 | 2,294,000 | 74,000 | ||
| total assets | 614,163,000 | 647,392,000 | 663,906,000 | 700,910,000 | 732,357,000 | 752,688,000 | 612,407,000 | 589,131,000 | 634,376,000 | 679,223,000 | 673,355,000 | 324,267,000 | 349,241,000 | 384,124,000 | 410,877,000 | 426,518,000 |
| liabilities and stockholders’ equity | ||||||||||||||||
| current liabilities: | ||||||||||||||||
| accounts payable | 5,352,000 | 4,520,000 | 4,637,000 | 6,833,000 | 3,049,000 | 6,636,000 | 1,054,000 | 3,146,000 | 3,372,000 | 2,424,000 | 465,000 | 6,320,000 | 2,438,000 | 7,077,000 | 3,579,000 | 1,530,000 |
| accrued expenses | 17,053,000 | 24,342,000 | 21,918,000 | 19,762,000 | 16,552,000 | 20,178,000 | 23,403,000 | 19,839,000 | 18,996,000 | 20,767,000 | 19,649,000 | 18,620,000 | 10,933,000 | 12,992,000 | 8,127,000 | 6,967,000 |
| deferred revenue, current | 19,060,000 | 3,605,000 | 5,719,000 | 3,479,000 | 1,473,000 | |||||||||||
| lease liability, current portion | 10,516,000 | 10,220,000 | 10,192,000 | 10,118,000 | 10,046,000 | 11,184,000 | 11,904,000 | 8,904,000 | ||||||||
| total current liabilities | 51,981,000 | 42,909,000 | 42,642,000 | 40,367,000 | 31,294,000 | 37,006,000 | 34,575,000 | 33,031,000 | 33,552,000 | 35,095,000 | 29,018,000 | 25,847,000 | 14,803,000 | 22,024,000 | 20,251,000 | 8,649,000 |
| long term lease liability | 58,120,000 | 59,541,000 | 60,887,000 | 62,183,000 | 63,454,000 | 64,715,000 | 66,689,000 | 67,819,000 | ||||||||
| success payment liability | 959,000 | 1,182,000 | 977,000 | 971,000 | 2,642,000 | 2,720,000 | 2,007,000 | 2,809,000 | 2,147,000 | 2,885,000 | 5,062,000 | 1,756,000 | 2,694,000 | 4,371,000 | 12,460,000 | |
| deferred revenue, non-current | 29,520,000 | 50,265,000 | 50,731,000 | 51,153,000 | 51,733,000 | 48,556,000 | 48,554,000 | 20,014,000 | 20,014,000 | 20,014,000 | 20,014,000 | |||||
| other long term liabilities | 70,000 | 95,000 | 118,000 | 142,000 | 165,000 | 189,000 | 213,000 | 236,000 | 283,000 | 331,000 | 354,000 | 377,000 | ||||
| total liabilities | 140,650,000 | 153,992,000 | 155,355,000 | 154,816,000 | 149,288,000 | 153,186,000 | 152,038,000 | 123,909,000 | 124,900,000 | 128,291,000 | 125,412,000 | 27,934,000 | 17,851,000 | 26,772,000 | 25,942,000 | 21,122,000 |
| commitments and contingencies | ||||||||||||||||
| stockholders’ equity: | ||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||
| common stock | 89,000 | 89,000 | 85,000 | 85,000 | 84,000 | 82,000 | 64,000 | 62,000 | 62,000 | 62,000 | 61,000 | 49,000 | 49,000 | 49,000 | 48,000 | 48,000 |
| additional paid-in capital | 1,247,078,000 | 1,235,897,000 | 1,200,302,000 | 1,189,470,000 | 1,176,526,000 | 1,143,453,000 | 956,855,000 | 916,109,000 | 905,863,000 | 895,801,000 | 851,954,000 | 555,184,000 | 549,089,000 | 544,381,000 | 540,402,000 | 538,109,000 |
| accumulated other comprehensive income | 393,000 | 428,000 | 1,143,000 | -615,000 | -500,000 | 272,000 | -228,000 | -2,000 | 3,000 | |||||||
| accumulated deficit | -774,047,000 | -743,014,000 | -692,979,000 | -642,846,000 | -593,041,000 | -544,305,000 | -495,953,000 | -450,195,000 | -396,212,000 | -344,237,000 | -303,152,000 | -257,962,000 | -217,016,000 | -186,850,000 | -155,513,000 | -132,764,000 |
| total stockholders’ equity | 473,513,000 | 493,400,000 | 508,551,000 | 546,094,000 | 583,069,000 | 599,502,000 | 460,369,000 | 465,222,000 | 509,476,000 | 550,932,000 | 547,943,000 | 296,333,000 | 331,390,000 | 357,352,000 | 384,935,000 | 405,396,000 |
| total liabilities and stockholders’ equity | 614,163,000 | 647,392,000 | 663,906,000 | 700,910,000 | 732,357,000 | 752,688,000 | 612,407,000 | 589,131,000 | 634,376,000 | 673,355,000 | 324,267,000 | 349,241,000 | ||||
| lease liability, current | 10,442,000 | 10,368,000 | 10,293,000 | |||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding | ||||||||||||||||
| accumulated other comprehensive loss | -597,000 | -754,000 | -237,000 | -694,000 | -920,000 | -938,000 | -732,000 | |||||||||
| other long-term assets | 709,000 | 410,000 | ||||||||||||||
| long-term lease liability | 68,927,000 | 70,014,000 | 71,011,000 | |||||||||||||
| other long-term liabilities | 260,000 | 307,000 | ||||||||||||||
| liabilities, and stockholders’ equity | ||||||||||||||||
| total liabilities, and stockholders’ equity | 679,223,000 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||
| operating lease obligations, current portion | 907,000 | 1,432,000 | 1,955,000 | 2,295,000 | ||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively | ||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at march 31, 2022 and december 31, 2021, respectively | ||||||||||||||||
| liabilities, convertible preferred stock, and stockholders’ equity | ||||||||||||||||
| deferred rent, current portion | 152,000 | |||||||||||||||
| deferred rent, net of current portion | 13,000 | |||||||||||||||
| antidilution rights liability | ||||||||||||||||
| convertible preferred stock | ||||||||||||||||
| stockholders’ equity | ||||||||||||||||
| total liabilities, convertible preferred stock, and stockholders’ equity | 384,124,000 | 410,877,000 | 426,518,000 | |||||||||||||
| success payment liability, current portion | 6,250,000 | |||||||||||||||
| operating lease obligations, net of current portion | 181,000 | |||||||||||||||
| success payment liability, net of current portion | 5,510,000 |
We provide you with 20 years of balance sheets for Verve Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verve Therapeutics. Explore the full financial landscape of Verve Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Verve Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.